Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids

source extracted confidence: high 2026-04-09
#adolescent #adult #c-reactive-protein #double-blind-method #fatty-acids-omega-3

Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids

Mossaheb et al., 2018 | Early Interv Psychiatry | Rct

Citation

Mossaheb Nilufar, Papageorgiou Konstantinos, ... Amminger G Paul. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. Early Interv Psychiatry. 2018-Feb;12(1):30-36. doi:10.1111/eip.12275

Abstract

AIM: The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra-high risk (UHR) for psychosis treated with ω-3 polyunsaturated fatty acids (PUFAs) versus placebo. METHODS: Data were derived from a randomized, double-blind, placebo-controlled trial conducted at an early psychosis unit. Eighty-one individuals, aged 13-25 years, at UHR for psychosis participated in a 12-week intervention trial of 1.2 g/day of ω-3 PUFAs (n = 41) versus placebo (n = 40). Lipid and C-reactive protein levels were collected at baseline and after 12 weeks. RESULTS: Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL-1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7). CONCLUSION: In this sample of UHR individuals, a 12-week intervention with ω-3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals.

Key Findings

Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL-1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7).

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population baseline tg levels above
Sample Size 41
Age Range aged 13-25
Condition See abstract

MeSH Terms

  • Adolescent
  • Adult
  • C-Reactive Protein
  • Double-Blind Method
  • Fatty Acids, Omega-3
  • Female
  • Humans
  • Male
  • Prodromal Symptoms
  • Psychotic Disorders
  • Triglycerides
  • Young Adult

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
  • Vertical: omega-3-schizophrenia

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09